Nanoparticle-Based Treatment in Glioblastoma
Glioblastoma (GB) is a malignant glioma associated with a mean overall survival of 12 to 18 months, even with optimal treatment, due to its high relapse rate and treatment resistance. The standardized first-line treatment consists of surgery, which allows for diagnosis and cytoreduction, followed by...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/13/9/1328 |
| _version_ | 1797579324142911488 |
|---|---|
| author | Diogo Roque Nuno Cruz Hugo Alexandre Ferreira Catarina Pinto Reis Nuno Matela Manuel Herculano-Carvalho Rita Cascão Claudia C. Faria |
| author_facet | Diogo Roque Nuno Cruz Hugo Alexandre Ferreira Catarina Pinto Reis Nuno Matela Manuel Herculano-Carvalho Rita Cascão Claudia C. Faria |
| author_sort | Diogo Roque |
| collection | DOAJ |
| description | Glioblastoma (GB) is a malignant glioma associated with a mean overall survival of 12 to 18 months, even with optimal treatment, due to its high relapse rate and treatment resistance. The standardized first-line treatment consists of surgery, which allows for diagnosis and cytoreduction, followed by stereotactic fractionated radiotherapy and chemotherapy. Treatment failure can result from the poor passage of drugs through the blood–brain barrier (BBB). The development of novel and more effective therapeutic approaches is paramount to increasing the life expectancy of GB patients. Nanoparticle-based treatments include epitopes that are designed to interact with specialized transport systems, ultimately allowing the crossing of the BBB, increasing therapeutic efficacy, and reducing systemic toxicity and drug degradation. Polymeric nanoparticles have shown promising results in terms of precisely directing drugs to the brain with minimal systemic side effects. Various methods of drug delivery that pass through the BBB, such as the stereotactic injection of nanoparticles, are being actively tested in vitro and in vivo in animal models. A significant variety of pre-clinical studies with polymeric nanoparticles for the treatment of GB are being conducted, with only a few nanoparticle-based drug delivery systems to date having entered clinical trials. Pre-clinical studies are key to testing the safety and efficacy of these novel anticancer therapies and will hopefully facilitate the testing of the clinical validity of this promising treatment method. Here we review the recent literature concerning the most frequently reported types of nanoparticles for the treatment of GB. |
| first_indexed | 2024-03-10T22:34:34Z |
| format | Article |
| id | doaj.art-c449d0b396cd401e81e6890e5c797df6 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-10T22:34:34Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-c449d0b396cd401e81e6890e5c797df62023-11-19T11:30:42ZengMDPI AGJournal of Personalized Medicine2075-44262023-08-01139132810.3390/jpm13091328Nanoparticle-Based Treatment in GlioblastomaDiogo Roque0Nuno Cruz1Hugo Alexandre Ferreira2Catarina Pinto Reis3Nuno Matela4Manuel Herculano-Carvalho5Rita Cascão6Claudia C. Faria7Department of Neurosurgery, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), 1649-028 Lisbon, PortugalInstituto de Biofísica e Engenharia Biomédica, IBEB, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, PortugalInstituto de Biofísica e Engenharia Biomédica, IBEB, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, PortugalInstituto de Biofísica e Engenharia Biomédica, IBEB, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, PortugalInstituto de Biofísica e Engenharia Biomédica, IBEB, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, PortugalDepartment of Neurosurgery, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), 1649-028 Lisbon, PortugalInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, PortugalDepartment of Neurosurgery, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), 1649-028 Lisbon, PortugalGlioblastoma (GB) is a malignant glioma associated with a mean overall survival of 12 to 18 months, even with optimal treatment, due to its high relapse rate and treatment resistance. The standardized first-line treatment consists of surgery, which allows for diagnosis and cytoreduction, followed by stereotactic fractionated radiotherapy and chemotherapy. Treatment failure can result from the poor passage of drugs through the blood–brain barrier (BBB). The development of novel and more effective therapeutic approaches is paramount to increasing the life expectancy of GB patients. Nanoparticle-based treatments include epitopes that are designed to interact with specialized transport systems, ultimately allowing the crossing of the BBB, increasing therapeutic efficacy, and reducing systemic toxicity and drug degradation. Polymeric nanoparticles have shown promising results in terms of precisely directing drugs to the brain with minimal systemic side effects. Various methods of drug delivery that pass through the BBB, such as the stereotactic injection of nanoparticles, are being actively tested in vitro and in vivo in animal models. A significant variety of pre-clinical studies with polymeric nanoparticles for the treatment of GB are being conducted, with only a few nanoparticle-based drug delivery systems to date having entered clinical trials. Pre-clinical studies are key to testing the safety and efficacy of these novel anticancer therapies and will hopefully facilitate the testing of the clinical validity of this promising treatment method. Here we review the recent literature concerning the most frequently reported types of nanoparticles for the treatment of GB.https://www.mdpi.com/2075-4426/13/9/1328glioblastomananoparticlesblood-brain barriertherapy delivery |
| spellingShingle | Diogo Roque Nuno Cruz Hugo Alexandre Ferreira Catarina Pinto Reis Nuno Matela Manuel Herculano-Carvalho Rita Cascão Claudia C. Faria Nanoparticle-Based Treatment in Glioblastoma Journal of Personalized Medicine glioblastoma nanoparticles blood-brain barrier therapy delivery |
| title | Nanoparticle-Based Treatment in Glioblastoma |
| title_full | Nanoparticle-Based Treatment in Glioblastoma |
| title_fullStr | Nanoparticle-Based Treatment in Glioblastoma |
| title_full_unstemmed | Nanoparticle-Based Treatment in Glioblastoma |
| title_short | Nanoparticle-Based Treatment in Glioblastoma |
| title_sort | nanoparticle based treatment in glioblastoma |
| topic | glioblastoma nanoparticles blood-brain barrier therapy delivery |
| url | https://www.mdpi.com/2075-4426/13/9/1328 |
| work_keys_str_mv | AT diogoroque nanoparticlebasedtreatmentinglioblastoma AT nunocruz nanoparticlebasedtreatmentinglioblastoma AT hugoalexandreferreira nanoparticlebasedtreatmentinglioblastoma AT catarinapintoreis nanoparticlebasedtreatmentinglioblastoma AT nunomatela nanoparticlebasedtreatmentinglioblastoma AT manuelherculanocarvalho nanoparticlebasedtreatmentinglioblastoma AT ritacascao nanoparticlebasedtreatmentinglioblastoma AT claudiacfaria nanoparticlebasedtreatmentinglioblastoma |